800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

view all Clinical Trials

Overview

This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.

Clinical Trial Information

Protocol

TIRB#: 31968

Phase

2

Condition(s)

Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF)

Investigator

Gerard Criner, MD

Coordinator

Kriti Mittal, Elaina Budny, Rachel Nwafo

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

A Randomised, Double-blind, Placebo-controlled, Dose-finding Study Evaluating Efficacy, Safety, and Tolerability of Different Oral Doses of BI 1819479 Over at Least 24 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)